-
公开(公告)号：US20210053908A1
公开(公告)日：2021-02-25
申请号：US16899376
申请日：2020-06-11
申请人： CORTEXYME, INC.
发明人： Andrei W. Konradi , Robert A. Galemmo, JR. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号： C07C233/62 , C07D213/82 , C07D239/34 , C07D239/36 , C07D413/12 , C07D257/04 , C07D261/12 , C07D213/70 , C07C317/28 , C07C233/78 , C07C235/10 , C07C235/50 , C07B59/00 , C07C237/42 , C07D401/12 , C07C381/00 , C07C323/42 , C07D213/65 , C07D213/68 , C07D239/38 , C07C247/18 , C07F5/02 , A61P31/04 , A61P25/00 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , C07C245/08 , C07C247/16 , C07C323/40 , C07D213/81
摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号：US10730826B2
公开(公告)日：2020-08-04
申请号：US16353786
申请日：2019-03-14
申请人： CORTEXYME, INC.
发明人： Andrei W. Konradi , Robert A. Galemmo, Jr. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号： C07C233/62 , C07D213/82 , C07D239/34 , C07D239/36 , C07D413/12 , C07D257/04 , C07D261/12 , C07D213/70 , C07C317/28 , C07C233/78 , C07C235/10 , C07C235/50 , C07B59/00 , C07C237/42 , C07D401/12 , C07C381/00 , C07C323/42 , C07D213/65 , C07D213/68 , C07D239/38 , C07C247/18 , C07F5/02 , A61P31/04 , A61P25/00 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , C07C245/08 , C07C247/16 , C07C323/40 , C07D213/81
摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号：US10676470B2
公开(公告)日：2020-06-09
申请号：US16399821
申请日：2019-04-30
申请人： Cortexyme, Inc.
IPC分类号： C07C233/62 , C07C233/78 , C07C247/16 , C07D417/12 , C07D277/64 , C07D409/12 , C07D213/50 , C07C247/18 , C07D277/24 , C07D213/53 , C07D277/28
摘要： The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：US20190210960A1
公开(公告)日：2019-07-11
申请号：US16353786
申请日：2019-03-14
申请人： CORTEXYME, INC.
发明人： Andrei W. Konradi , Robert A. Galemmo, JR. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号： C07C233/62 , A61K45/06 , A61K31/165 , C07C233/78 , A61K31/167 , C07C247/16 , A61K31/655 , C07D257/04 , A61K31/41 , C07C323/40 , C07C317/28 , C07C235/50 , C07D213/81 , A61K31/44 , C07D213/82 , C07D239/36 , A61K31/513 , A61K31/4406 , C07C245/08 , C07C235/10 , C07D261/12 , A61K31/42 , A61K31/4402 , A61K31/4409 , C07D413/12 , A61K31/4439 , C07D239/34 , A61K31/505 , C07D213/70 , A61P31/04 , A61P25/00
摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号：US20220204457A1
公开(公告)日：2022-06-30
申请号：US17441572
申请日：2020-03-20
申请人： Cortexyme, Inc.
IPC分类号： C07D239/34 , C07C279/28 , C07C279/24 , C07C279/12 , C07D213/68 , C07D213/82 , C07D261/12
摘要： Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：US11059786B2
公开(公告)日：2021-07-13
申请号：US16678700
申请日：2019-11-08
申请人： Cortexyme, Inc.
IPC分类号： C07D213/73 , C07D217/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D413/12 , C07D491/048 , A61P25/28
摘要： The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：US20190322659A1
公开(公告)日：2019-10-24
申请号：US16399821
申请日：2019-04-30
申请人： Cortexyme, Inc.
IPC分类号： C07D417/12 , C07D213/53 , C07D409/12 , C07D277/24 , C07C247/18 , C07D277/28 , C07D277/64 , C07C233/62 , C07C233/78 , C07C247/16 , C07D213/50
摘要： The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：US12110263B2
公开(公告)日：2024-10-08
申请号：US17740260
申请日：2022-05-09
申请人： CORTEXYME, INC.
发明人： Andrei W. Konradi , Robert A. Galemmo, Jr. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号： C07C233/62 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , A61P25/00 , A61P31/04 , C07B59/00 , C07C233/78 , C07C235/10 , C07C235/50 , C07C237/42 , C07C245/08 , C07C247/16 , C07C247/18 , C07C317/28 , C07C323/40 , C07C323/42 , C07C381/00 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/81 , C07D213/82 , C07D239/34 , C07D239/36 , C07D239/38 , C07D257/04 , C07D261/12 , C07D401/12 , C07D413/12 , C07F5/02
CPC分类号： C07C233/62 , A61K31/165 , A61K31/167 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/505 , A61K31/513 , A61K31/655 , A61K45/06 , A61P25/00 , A61P31/04 , C07B59/001 , C07C233/78 , C07C235/10 , C07C235/50 , C07C237/42 , C07C245/08 , C07C247/16 , C07C247/18 , C07C317/28 , C07C323/40 , C07C323/42 , C07C381/00 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/81 , C07D213/82 , C07D239/34 , C07D239/36 , C07D239/38 , C07D257/04 , C07D261/12 , C07D401/12 , C07D413/12 , C07F5/02 , C07C2601/08
摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号：US20230142714A1
公开(公告)日：2023-05-11
申请号：US17740260
申请日：2022-05-09
申请人： CORTEXYME, INC.
发明人： Andrei W. Konradi , Robert A. Galemmo, JR. , Stephen S. Dominy , Casey C. Lynch , Leslie J. Holsinger
IPC分类号： C07C233/62 , C07D401/12 , A61K31/655 , A61K31/165 , C07C245/08 , C07C323/42 , C07C247/18 , C07D261/12 , C07C237/42 , C07D213/82 , A61K31/513 , C07D239/34 , C07D239/36 , A61P31/04 , C07F5/02 , A61K31/4402 , A61K31/4439 , A61K31/4409 , C07D413/12 , C07C323/40 , A61K31/4406 , A61K31/505 , C07C233/78 , C07C235/50 , A61K31/44 , C07D257/04 , A61K45/06 , C07D239/38 , C07C317/28 , A61K31/42 , C07C381/00 , C07D213/81 , A61K31/41 , C07D213/65 , C07C247/16 , C07D213/70 , C07B59/00 , A61K31/167 , C07C235/10 , C07D213/68 , A61P25/00
CPC分类号： C07C233/62 , C07D401/12 , A61K31/655 , A61K31/165 , C07C245/08 , C07C323/42 , C07C247/18 , C07D261/12 , C07C237/42 , C07D213/82 , A61K31/513 , C07D239/34 , C07D239/36 , A61P31/04 , C07F5/02 , A61K31/4402 , A61K31/4439 , A61K31/4409 , C07D413/12 , C07C323/40 , A61K31/4406 , A61K31/505 , C07C233/78 , C07C235/50 , A61K31/44 , C07D257/04 , A61K45/06 , C07D239/38 , C07C317/28 , A61K31/42 , C07C381/00 , C07D213/81 , A61K31/41 , C07D213/65 , C07C247/16 , C07D213/70 , C07B59/001 , A61K31/167 , C07C235/10 , C07D213/68 , A61P25/00 , C07C2601/08
摘要： The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
-
公开(公告)号：US11332464B2
公开(公告)日：2022-05-17
申请号：US16866022
申请日：2020-05-04
申请人： Cortexyme, Inc.
IPC分类号： C07D417/12 , C07D277/28 , C07D277/24 , C07C233/78 , C07D277/64 , C07D409/12 , C07D213/50 , C07C247/16 , C07C233/62 , C07C247/18 , C07D213/53
摘要： The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.016 秒)
